Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, eculizumab (Soliris®) cannot be endorsed for use within NHS Wales in adults for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease. |
||
|
||
Medicine details |
||
| Medicine name | eculizumab (Soliris®) | |
| Formulation | 300 mg concentrate for solution for infusion | |
| Reference number | 2909 | |
| Indication | In adults for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease |
|
| Company | Alexion Pharma UK Ltd | |
| BNF chapter | Eye | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 12/12/2019 | |